Compare TELA & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TELA | ATRA |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.5M | 38.9M |
| IPO Year | 2019 | 2014 |
| Metric | TELA | ATRA |
|---|---|---|
| Price | $0.57 | $4.89 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 4 | 2 |
| Target Price | $2.00 | ★ $5.00 |
| AVG Volume (30 Days) | 152.0K | ★ 229.0K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 37.59 | ★ 122.52 |
| EPS | N/A | ★ 2.57 |
| Revenue | $80,275,000.00 | ★ $120,772,000.00 |
| Revenue This Year | $17.75 | N/A |
| Revenue Next Year | $16.45 | N/A |
| P/E Ratio | ★ N/A | $1.94 |
| Revenue Growth | ★ 15.84 | N/A |
| 52 Week Low | $0.50 | $3.92 |
| 52 Week High | $2.19 | $19.15 |
| Indicator | TELA | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 38.49 | 46.83 |
| Support Level | N/A | $4.70 |
| Resistance Level | $1.24 | $5.65 |
| Average True Range (ATR) | 0.12 | 0.45 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 24.18 | 32.09 |
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).